Eli Lilly and Pfizer announced Oct. 27 that they ceased the development of tanezumab, a pain drug the two companies had been developing for osteoarthritis.
https://www.pharmalive.com/wp-content/uploads/2021/10/Eli-Lilly-and-Pfizer-Put-Osteoarthritis-Pain-Drug-Out-of-its-Misery-BioSpace-10-27-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-10-27 14:44:072021-10-27 14:49:58Eli Lilly and Pfizer End Tanezumab Development